Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Cancers

Jameel Singh¹  Daryl Ramai²  Samridhi Sinha²  Rita Golfieri³  Matteo Renzulli³  Nicolò Brandi³  Anna Maria Ierardi⁴  Elisa Albertini⁵  Rodolfo Sacco⁶  Antonio Facciorusso⁶ 

[1] Department of Internal Medicine, Mather Hospital, Northwell Health, Port Jefferson, New York, NY 11777, USA;Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, NY 11201, USA;Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy;Diagnostic and Interventional Radiology, ASST Santi Paolo e Carlo, San Paolo Hospital, 20142 Milan, Italy;Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy;Section of Gastroenterology, Department of Medical Sciences, University of Foggia, 71122 Foggia, Italy;

关键词: cholangiocarcinoma;    combined hepatocellular cholangiocarcinoma;    biliary tract;   

DOI  :  10.3390/cancers13133336

来源: DOAJ

【 摘 要 】

Cholangiocarcinoma (CCA) is a primary and aggressive cancer of the biliary tree. Combined hepatocellular cholangiocarcinoma (CHC) is a distinctive primary liver malignancy which has properties of both hepatocytic and cholangiocytic differentiation. CHC appears to have a worse prognosis compared to hepatocellular carcinoma, and similar to that of intrahepatic CCA. While significant advances have been made in understanding the pathophysiology and treatment of these two tumor types, their prognosis remains poor. Currently, liver resection is the primary treatment modality; however, only a minority of patients are eligible for surgery. However, the use of locoregional therapies proves an alternative approach to treating locally advanced disease with the aim of converting to resectability or even transplantation. Locoregional therapies such as transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), and photodynamic therapy (PDT) can provide patients with tumor control and increase the chances of survival. In this review, we appraise the evidence surrounding the use of locoregional therapies in treating patients with CCA and CHC.

【 授权许可】

Unknown